The Shkreli Pill

ALL EPISODES HERE:The Shkreli Pill | Listen to the Podcast on SpotifyIn this episode, Martin examines Nvidia’s valuation through the lens of Warren Buffett’s value investing philosophy, questioning what price a disciplined investor might be willing to pay for the semiconductor giant. He explores Nvidia’s earnings potential, competitive advantages, AI-driven growth expectations, and the importance of maintaining a margin of safety. Martin also discusses Spruce Biosciences and the potential implications of splitting or restructuring its assets, examining how such a move could affect shareholder value. The episode concludes with an analysis of Akamai Technologies, covering its business fundamentals, competitive position, valuation, and potential investment opportunities.

In this episode, Martin reacts to a sharp stock market selloff and examines whether the downturn signals the beginning of a prolonged bear market or a temporary correction. He discusses the factors driving investor fear, including elevated valuations, economic uncertainty, and selling pressure across major technology stocks. Martin also explores potential market scenarios, the risks of further declines, and the opportunities that can emerge during periods of extreme volatility, while sharing his perspective on whether investors should prepare for more downside or a possible recovery.

In this episode, Martin discusses Intel reportedly losing a major chip contract and examines what it could mean for the company’s foundry ambitions and competitive position. He also explores Tesla’s relationship with TSMC and its implications for future semiconductor and AI hardware demand, before outlining his bearish thesis on Wolfspeed, focusing on its financial position, capital requirements, competitive pressures, and valuation.

This compilation brings together Martin’s discussions on why protecting capital and limiting losses can be more important than maximizing gains. Across a range of clips, he explores position sizing, diversification, drawdowns, expected value, and risk management, explaining how avoiding large losses can preserve compounding and improve long-term performance. The episode also highlights the importance of discipline, probability, and knowing when to reduce exposure or exit a losing position.

In this episode, Martin discusses Toshiba’s expansion plans and the potential implications for semiconductor supply, pricing, and investor sentiment across the memory market. He also examines Liquidia (LQDA) following its substantial gains and evaluates whether its valuation can be supported by future growth, before turning to Nektar Therapeutics (NKTR) and outlining his concerns about the company’s drug pipeline, clinical risks, and investment outlook.

In this episode, Martin explains why he believes increasing Chinese semiconductor supply could create significant pressure for Micron and the broader memory market. He outlines his bearish outlook on semiconductor stocks, examining supply growth, memory pricing, capital spending, and industry cycles, before discussing ASML and Micron (MU) and the risks and catalysts shaping his current short theses.

In this episode, Martin discusses how investors can evaluate buying opportunities during sharp market selloffs and determine when fear may have pushed prices below underlying value. He shares lessons on valuation, market psychology, position sizing, and managing risk when trading against panic, before analyzing Liquidia and examining its clinical prospects, competitive position, catalysts, valuation, and the risks shaping his investment outlook.

In this episode, Martin examines Cerebras and whether its AI chip architecture could challenge Nvidia’s dominance in accelerated computing. He also lays out his bullish thesis on MongoDB and discusses the factors that could support a $400 valuation target, before turning to Ginkgo Bioworks and explaining his bearish outlook on the company, including its business model, financial performance, valuation, and investment risks.

In this episode, Martin reflects on a major loss from his short position in Kodiak Sciences and examines how a short squeeze moved the trade against him. He discusses position sizing, risk management, conviction, and the lessons he draws from losing millions on the position before turning to Nvidia, where he explores ways investors can search for alpha by analyzing expectations, valuation, AI demand, and potential market inefficiencies.

In this episode, Martin reflects on a costly short position in Kodiak Sciences and examines what went wrong with the trade, including the risks of conviction, timing, and unexpected catalysts. He also discusses the possibility of OpenAI eventually going public and what such a move could mean for investors, before explaining why he believes many financial models fail to capture reality and how assumptions, probabilities, and changing business conditions can undermine even detailed forecasts.